• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Hemlibra (emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: chronic” Lyme disease: current state of knowledge and overview of the different perspectives]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2021     NIHR Health Technology Assessment programme Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     NIHR Health Technology Assessment programme A multicentre randomised controlled trial of induced endometrial trauma in women undergoing first time In Vitro Fertilisation (IVF)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     NIHR Health Technology Assessment programme Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Facilitating the return to work of NHS staff with common mental health disorders: a feasibility study
2021     Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021     NIHR Health Technology Assessment programme QUIDS Quantitative fibronectin to help decision-making in women with symptoms of preterm labour
2021     NIHR Health Technology Assessment programme The Invasive Dentistry Endocarditis Association Study: the IDEA Study
2021     Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021     NIHR Health Technology Assessment programme Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
2021     NIHR Health Technology Assessment programme Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
2021     Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Internet-based psychological treatment for anxiety and depression]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Scottish Health Technologies Group (SHTG) NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-65]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostics and treatment of provoked vestibulodynia]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol for the treatment of Dravet syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Continuity of care]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogs in association with high protein diet in chronic kidney failure]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol for the treatment of Lennox-Gastaut syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® motorized intramedullary nail system for limb-length discrepancy]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Lipoedema – diagnosis, treatment, and experiences]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Direct-acting oral anticoagulants for postoperative thrombosis prophylaxis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Multimodal and interdisciplinary interventions for long term pain]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing for lynch syndrome in colorectal cancer and family members]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Caesarean section on maternal request]
2021     NIHR Public Health Research (PHR) programme School-based interventions to prevent anxiety, depression and conduct disorder in children and young people: a systematic review and network meta-analysis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (interstitial lung disease) - Addendum to Commission A20-71]
2021     Center for Evidence-based Practice (CEP) Opioid pain assessment
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Center for Evidence-based Practice (CEP) Effectiveness of intra-operative antimicrobial irrigation to prevent surgical site infection in clean surgeries
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment and rehabilitation of people with fibromyalgia]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: long-term left ventricular assist devices, real-world evolving portrait of use and outcomes in Québec from 2010 to 2017]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermal ablation of the duodenal mucosa in type 2 diabetes - Assessment according to §137h Social Code Book V]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Programs for preventing suicide and suicide attempt in children]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irreversible electroporation for chronic bronchitis - Assessment according to §137h Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: alcohol withdrawal and relapse prevention]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCT
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of using mpMRI for the diagnostic investigation of prostate cancer - mpMRI and prostate cancer diagnosis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     NIHR Public Health Research (PHR) programme A cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of the GoActive programme to increase physical activity among 13-14 year-old adolescents
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Newborn screening for classic congenital adrenal hyperplasia. Update and assessment of regional programs]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bempedoic acid (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optimal use of immunoglobulins in rheumatology. Report in support of the optimal use guide English summary]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V]
2021     NIHR Health Technology Assessment programme Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of immunoglobulins in rheumatology. Systematic review report]
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-78]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Robotics and functional electrical stimulation for stroke rehabilitation: systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2021     Center for Evidence-based Practice (CEP) Ambulatory blood glucose checks
2021     Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis) - Addendum to Commissions G20-18, G20-20, A20-77, A20-83]
2021     NIHR Public Health Research (PHR) programme A randomised controlled trial and economic evaluation of a community-based physical activity intervention to prevent mobility-related disability for retired older people. The REACT (REtirement in ACTion) study
2021     Center for Evidence-based Practice (CEP) Prevention of opioid-induced respiratory depression (OIRD) in hospital care
2021     Agency for Care Effectiveness (ACE) Metformin extended release for treating type 2 diabetes mellitus
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Addendum to Commission A20-83]
2021     NIHR Health Technology Assessment programme PRODIGY: Prevention and treatment of long term social disability amongst young people with emerging severe mental illness: A randomised controlled trial
2021     Center for Evidence-based Practice (CEP) Fall prevention in ambulatory care facilities
2021     Agency for Care Effectiveness (ACE) Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (psoriatic arthritis) - Addendum to Commission A20-80]
2021     Center for Evidence-based Practice (CEP) Triaging COVID-19 in the emergency department
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active psoriatic arthritis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Addendum to Commission A20-77]
2021     Center for Evidence-based Practice (CEP) Critical value thresholds
2021     Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alpelisib (breast cancer) - Addendum to Commission A20-81]
2021     NIHR Health Services and Delivery Research programme The TRECA study: TRials Engagement in Children and Adolescents
2021     Health Technology Wales (HTW) Corneal crosslinking to treat adults and children with keratoconus
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Health Technology Wales (HTW) Freestyle Libre flash glucose monitoring for the management of diabetes
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]